Michael Singer-BrainScope-An AI-Based, Handheld Device for Objectively and Reliably Assessing Traumatic Brain Injuries

In the US alone, approximately five to 10 million people require a brain injury assessment and potential intervention every year; globally, that number rises to somewhere between 75 and 100 million. These numbers may shock you, but what's perhaps even more shocking is that as it currently stands, brain injury assessments are highly subjective, relying more upon a particular clinician's capabilities and experience with diagnosing brain injuries than on any form of objective measurement. This has not only led to misdiagnoses, but an extreme overuse of CAT scan technology.

Michael Singer is the CEO of BrainScope, a company that's developed an AI-based, non-invasive, handheld device capable of helping clinicians objectively and reliably determine whether or not a patient actually needs a CAT scan to look for bleeding in the brain, and identify whether or not a patient has suffered from a functional brain injury, such as a concussion, which is something that CAT scans can't do.

Developed in coordination with military and clinical partners, the BrainScope device is applied to a patient's forehead in order to measure the electrical activity in their brain and provide as assessment as to whether or not the patient is at risk of a bleed in the brain, and whether or not the patient has suffered a concussion. As a whole, this device provides a panel of capabilities that allow clinicians to feel more confident in making decisions about what's best for an individual patient.

Tune in for all the details about this exciting new technology, and visit www.brainscope.com to learn more.